Abstract
High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Allylbenzene Derivatives
-
Anisoles / chemistry
-
Anisoles / pharmacology
-
Anticholesteremic Agents / chemistry*
-
Anticholesteremic Agents / pharmacology
-
Binding Sites
-
Cardiovascular Diseases / drug therapy
-
Cholesterol / metabolism
-
Databases, Protein
-
Humans
-
Hydroxymethylglutaryl CoA Reductases / chemistry*
-
Hydroxymethylglutaryl CoA Reductases / metabolism
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
-
Lipoproteins, LDL / metabolism
-
Structure-Activity Relationship
Substances
-
Allylbenzene Derivatives
-
Anisoles
-
Anticholesteremic Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipoproteins, LDL
-
asarone
-
Cholesterol
-
Hydroxymethylglutaryl CoA Reductases